Back to search
FDAFDA · Food and drugs·Recall number D-0512-2024

Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single-Use vials for Intraocular Injection, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-640-01

Published June 5, 2024 · Recall initiated: May 14, 2024

Summary

FDA records drug Class II recall D-0512-2024, published June 5, 2024 and initiated May 14, 2024. Recalling firm: Imprimis NJOF, LLC; Status: Ongoing; Reported quantity: 14,180 vials; Lot: Lot #: 23APR033, Exp. Date 5/1/24; 23JUN001, Exp. Date 6/5/24. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Imprimis NJOF, LLC
Distributor
Nationwide within the United States
Lot
Lot #: 23APR033, Exp. Date 5/1/24; 23JUN001, Exp. Date 6/5/24
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Epinephrine-Lidocaine HCl 0.25 mg/mL and 7.5 mg/mL Preservative-Free 1mL Single-Use vials for Intraocular Injection, Imprimis NJOF, LLC. 1705 Route 46 West, unit 6B, Ledgewood, NJ 07852, NDC 71384-640-01 recalled?

Yes. FDA published recall D-0512-2024 on June 5, 2024. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated